BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2018

Jun 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2018-06-14

Reporting Person: FUCHS HENRY J (President, Worldwide R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-14	Common Stock	M	2000	$21.510	Acquired	157167	Direct
2018-06-14	Common Stock	S	2000	$90.00	Disposed	155167	Direct
2018-06-14	Common Stock	M	3775	$26.490	Acquired	158942	Direct
2018-06-14	Common Stock	S	3775	$90.00	Disposed	155167	Direct
2018-06-14	Common Stock	M	2669	$37.46	Acquired	157836	Direct
2018-06-14	Common Stock	S	2669	$90.00	Disposed	155167	Direct
2018-06-14	Common Stock	M	1875	$26.49	Acquired	157042	Direct
2018-06-14	Common Stock	S	1875	$90.00	Disposed	155167	Direct
2018-06-14	Common Stock	M	20681	$37.46	Acquired	175848	Direct
2018-06-14	Common Stock	S	20681	$90.0041	Disposed	155167	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-14	Stock Option (Right to buy Common Stock)	$21.510	M	2000	Disposed	2020-05-11	Common Stock (2000)	Direct
2018-06-14	Stock Option (Right to buy Common Stock)	$26.49	M	3775	Disposed	2021-05-11	Common Stock (3775)	Direct
2018-06-14	Stock Option (Right to buy Common Stock)	$37.46	M	2669	Disposed	2022-05-07	Common Stock (2669)	Direct
2018-06-14	Stock Option (Right to buy Common Stock)	$26.49	M	1875	Disposed	2021-05-11	Common Stock (1875)	Direct
2018-06-14	Stock Option (Right to buy Common Stock)	$37.46	M	20681	Disposed	2022-05-07	Common Stock (20681)	Direct

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on May 30, 2018.

F2: The price in column 4 is the weighted average price. The price actually received ranged from $90.00 to $90.07. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F3: Reflects the number of options outstanding after the transactions from this specific stock option grant.